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AntimicrobialAbstract 2-(Phenoxymethyl)-1H-benzimidazole (3) obtained by acidic condensation of o-phenylene
diamine with phenoxyacetic acid, was reacted with ethyl chloroacetate under anhydrous condition to
get ethyl [2-(phenoxymethyl)-1H-benzimidazol-1-yl]acetate (4). The ethyl [2-(phenoxymethyl)-1H-
benzimidazol-1-yl]acetate (4) on treatment hydrazine hydrate gave 2-[2-(phenoxymethyl)-1Hbenzimi-
dazol-1-yl]acetohydrazide (5). The acid hydrazide group of 5 was cyclocondensed with various aro-
matic acids in presence of phosphorous oxychloride to get the titled compounds (6a–p). The
structures of all the compounds were established on the basis of elemental and spectral analysis.
The synthesized compounds were evaluated for their antimicrobial activity. The compound 6d, 6f,
6h and 6d, 6h and 6I a is most active compounds against Escherichia coli and Staphylococcus aureus
respectively. The compound 6d, 6f and 6l ismost active againstCandida albicans andAspergillus ﬂavus.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Benzimidazole and oxadiazole were reviewed for biological
activity and found that both heterosystems possess a broadspectrum of biological activities viz Antimicrobial (Kumar
et al., 2006; Shetgiri and Kokitkar, 2001; Kazimierczuk
et al., 2002; Kilcigil et al., 1999; Tuncbilek et al., 2009; Ansari
and Lal 2009a,b; Ozden et al., 2005; Kilcigil and Altanlar,
2003; Naik and Chikhalia 2007), anticonvulsant (Chimirri
et al., 2002; Singh 1970; Chimirri et al., 1989), antitubercular
(Foks et al., 2006; Gill et al., 2008), antiviral (Starcevic
et al., 2007), anticancer (Demirayak et al., 2002), anti-
inﬂammatory analgesic (Khan and Nandan 1997; Evans
et al., 1996) etc. It was hypothesized that the chemical combi-
nation of both the systems in one compound may prove to be a
breakthrough for antimicrobial activity. Further literature
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ers reported biological properties of such compounds as anti-
microbial (Ansari and Lal 2009a,b; El-masry et al., 2000),
antitubercular (Kaghthara et al., 1999) etc. These evidence
boosted us to carry out synthetic work for the titled compound
to evaluate their antimicrobial/antibacterial potential.
2. Experimental
o-Phenylenediamine, phenoxyacetic acid, chloroethylacetate,
hydrazine hydrate, phosphorous oxychloride, methanol, etha-
nol, sodiumbicarbonate, aromatic acids, heating mantle, con-
denser, bacterial and fungal strains. Melting points were
determined in open capillary using melting point apparatus
and are uncorrected. The Proton Magnetic Resonance
(1HNMR) spectra were recorded on a Bruker 300 MHz instru-
ment in DMSO-d6 using tetramethylsilane as internal stan-
dard. The Infrared spectra of compounds were recorded in
KBr on a Perkin–Elmer FTIR Spectrometer. To monitor the
reactions and to conﬁrm the purity of the compounds TLC
(Solvent System Toluene: ethyacetate: formic acid 5:4:1) was
performed and iodine/UV Chamber was used for visualization
of spots.
2.1. Synthesis of 2-(phenoxymethyl)-1H-benzimidazole (3)
A mixture of o-phenylenediamine 1 (0.05 mol; 5.40 g) and phe-
noxyacetic acid 2 (0.05 mol; 7.60 g) was reﬂuxed in 4 N HCl
for 4 h on a heating mantle. After completion of reaction, solu-
tion was poured onto crushed ice, ammonia solution was added
drop wise to neutralize and the resulting solid was ﬁltered,
washed with cold water, dried and recrystallized. yield 85%,
m.p. 160–164, IR (KBr) cm1: 1241 (C–O), 1545 (C‚N), 3444
(N–H): 1H-NMR (DMSO-d6) d ppm: 5.31 (s, 2H, OCH2),
6.95–7.66 (m, 9H, aromatic), 12.68 (s, 1H, NH); EI-MS 224
(M+); Anal calcd for C14H12N2O: C, 74.98; H,5.39; N, 12.49;
O, 7.13 Found: C, 74.99; H,5.36; N, 12.49; O, 7.11.
2.1.1. Synthesis of ethyl [2-(phenoxymethyl)-1H-benzimidazol-
1-yl]acetate (4)
To a suspension of 2-(phenoxymethyl)-1H-benzimidazole 3
(0.01 mol; 2.24 g), anhydrous potassium carbonate (2 g) in dry
acetone, ethyl chloroacetate (0.01 mol; 1.2 ml) was added drop
wise at room temperature for a period of 20–30 min. The reac-
tion mixture was stirred at room temperature for 10–12 h. The
inorganic solid was ﬁltered off and the ﬁltrate was concentrated
under reduced pressure. Yield 73%, mp 88–92, IR (KBr) cm1:
1241 (C–O), 1550 (C‚N), 1650 (C‚O): 1H-NMR (DMSO-d6)
d ppm: 5.21 (s, 2H, OCH2), 6.95–7.63 (m, 9H, aromatic), 4.120
(m, 2H, CH2), 1.45 (m, 3H, CH3), EI-MS 310 (M
+); Anal calcd
for C18H18N2O3: C, 69.66; H, 5.85; N, 9.03; O, 15.47. Found: C,
69.65; H, 5.84; N, 9.06; O, 15.45.
2.1.2. Synthesis of 2-[2-(phenoxymethyl)-3H-indol-3-yl]
acetohydrazide (5)
To an ethanolic solution of ethyl [2-(phenoxymethyl)-1H-ben-
zimidazol-1-yl]acetate 4 (0.01 mol; 3.10 g), hydrazine hydrate
(98%) (0.01 mol; 0.49 ml) was added and the mixture was re-
ﬂuxed for 3 h. After completion of the reaction, the mixture
was cooled and the solid so obtained was ﬁltered, washed withcold water and recrystallized from methanol. Yield 82%; m.p.
178–180, IR (KBr) cm1: 1032 (N–N), 1240 (C–O), 1600
(C‚N); 1666 (C‚O), 3044 (CH–Ar), 3291 (N–H); 1H-NMR
(DMSO-d6) d ppm: 2.54 (s, 1H, NH2), 4.95 (s, 2H, CH2),
5.38 (s, 2H, OCH2), 6.94–7.66 (m, 9H, aroamtic), 9.51 (s,
1H, CONH), EI-MS 296 (M+); Anal calcd for C16H16N4O2:
C, 64.85; H, 5.44; N, 18.91; O, 10.80 Found: C, 64.81; H,
5.43; N, 18.94; O, 10.82.
2.1.3. General procedure for the synthesis of compounds (6a–p)
A mixture of 2-[2-(phenoxymethyl)-1H-benzimidazol-1-
yl]acetohydrazide 5 (0.0025 mol; 0.738 g) and suitable aro-
matic acid (0.0025 mol) was reﬂuxed in the presence of POCl3
(5 ml) for 5 h at a temperature of 110–120 C. After comple-
tion of reaction, the mixture was cooled at room temperature
and poured onto crushed ice. On basiﬁcation with sodium
bicarbonate (5%), a solid mass was so separated out which
was ﬁltered to get crude product. Finally the product was
heated with charcoal in hydrated ethanol and then re-crystal-
lized from ethanol to obtain 6a–p.
2.1.3.1. Synthesis of 2-(phenoxymethyl)-1-[(5-phenyl-1,3,4-
oxadiazol-2-yl) methyl] -1H-benzimidazole (6a). Percentage
yield 84% m.p. 148–152 C IR (KBr) cm1: 1034 (N–N),
1241 (C–O), 1602 (C‚N); 1H-NMR (DMSO-d6) d ppm:
5.52 (s, 2H, CH2), 6.04 (s, 2H, OCH2), 7.00–7.81 (m, 14H, aro-
matic); EI-MS 382 (M+); Anal calcd for C23H18N4O2: C,
72.24; H, 4.74; N, 14.65; O, 8.37 Found: C, 72.21; H, 4.72;
N, 14.60; O, 8.36.
2.1.3.2. Synthesis of 2-(phenoxymethyl)-1-[{5-(2-methyl-
phenyl)-1,3,4-oxadiazol-2-yl}methyl]-1H-benzimidazole (6b).
Percentage yield 60%; m.p. 138–140 C, IR (KBr) cm1: 1034
(N–N), 1239 (C–O), 1593 (C‚N), 3056 (CH–Ar); 1H-NMR
(DMSO-d6) d ppm: 2.48 (s, 3H, CH3), 5.45 (s, 2H, CH2), 5.93
(s, 2H, OCH2), 6.83–7.59 (m, 13H, aromatic), EI-MS 397
(M+ + 1). Anal calcd for C24H20N4O2: C, 72.71; H, 5.08; N,
14.13; O, 8.07 Found: C, 72.74; H, 5.11; N, 14.15; O, 8.10.
2.1.3.3. Synthesis of 2-(phenoxymethyl)-1-[{5-(3-methyl-
phenyl)-1,3,4-oxadiazol-2-yl}methyl]-1H-benzimidazole (6c).
Percentage yield 60%; m.p. 170–172 C, IR (KBr) cm1:
1031 (N–N), 1238 (C–O), 1600 (C‚N), 3032 (CH–Ar); 1H-
NMR (DMSO-d6) d ppm: 3.21–3.38 (s, 3H, CH3, Merged with
H2O in DMSO), 5.50 (s, 2H, CH2), 6.03 (s, 2H, OCH2), 6.99–
7.72 (m, 13H, aromatic), EI-MS 397 (M+ + 1). Anal calcd for
C24H20N4O2: C, 72.71; H, 5.08; N, 14.13; O, 8.07 Found: C,
72.74; H, 5.14; N, 14.12; O, 8.16.
2.1.3.4. Synthesis of 2-(phenoxymethyl)-1-[{5-(4-methyl-
phenyl)-1,3,4-oxadiazol-2-yl}methyl]-1H-benzimidazole (6d).
Percentage yield 66%; m.p. 164–168 C, IR (KBr) cm1:
1237 (N–N),1277 (C–O), 1654 (C‚N); 1H-NMR (DMSO-
d6) d ppm: 2.37 (s, 3H, CH3), 5.50 (s, 2H, CH2), 6.02 (s, 2H,
OCH2), 6.91–7.71 (m, 13H, aromatic); EI-MS 397
(M+ + 1); Anal calcd for C24H20N4O2: C, 72.71; H, 5.08; N,
14.13; O, 8.07 Found: C, 72.75; H, 5.16; N, 14.09; O, 8.05.
2.1.3.5. Synthesis of 1-[{5-(2-chlorophenyl)-1,3,4-oxadiazol-2-
yl}methyl]-2-(phenoxymethyl)-1H-benzimidazole (6e). Per-
centage yield 72%; m.p. 170–173 C, IR (KBr) cm1: 737
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(DMSO-d6) d ppm: 5.50 (s, 2H, CH2), 6.07 (s, 2H, OCH2),
6.91–7.78 (m,13H, aromatic), EI-MS 417 (M+ + 1); Anal
calcd for C23H17ClN4O2: C, 66.27, H, 4.11; Cl, 8.50; N,
13.44; O, 7.68 Found: C, 66.23, H, 4.13; Cl, 8.55; N, 13.46;
O, 7.69.
2.1.3.6. Synthesis of 1-[{5-(4-chlorophenyl)-1,3,4-oxadiazol-2-
yl}methyl]-2-(phenoxymethyl)-1H-benzimidazole (6f). Per-
centage yield 69%; m.p.236–244 C, IR (KBr) cm1: 740 (C–
Cl), 1092 (N–N), 1238 (C–O), 1608 (C‚N), 3155 (CH–Ar);
1H-NMR (DMSO-d6) d ppm: 5.47 (s, 2H, CH2), 6.01 (s, 2H,
OCH2), 6.87–7.78 (m, 13H, aromatic), EI-MS 417
(M+ + 1). Anal calcd for C23H17ClN4O2: C, 66.27, H, 4.11;
Cl, 8.50; N, 13.44; O, 7.68 Found: C, 66.28, H, 4.10; Cl,
8.52; N, 13.45; O, 7.70.
2.1.3.7. Synthesis of 1-[{5-(2-bromophenyl)-1,3,4-oxadiazol-2-
yl}methyl]-2-(phenoxymethyl)-1H-benzimidazole (6g). Per-
centage yield 80%; m.p. 160–164 C, IR (KBr) cm1: 738
(C-Br), 1082 (N–N), 1240 (C–O), 1592 (C‚N), 3062 (CH–Ar);
1H-NMR (DMSO-d6) d ppm: 5.50 (s, 2H, CH2), 6.08 (s, 2H,
OCH2), 6.88–7.83 (m, 13H, aromatic), EI-MS 461
(M+ + 1). Anal calcd for C23H17BrN4O2: C, 59.88; H, 3.71;
Br, 17.32; N, 12.15; O, 6.94 Found: C, 59.85; H, 3.74; Br,
17.30; N, 12.14; O, 6.91.
2.1.3.8. Synthesis of 1-[{5-(4-bromophenyl)-1,3,4-oxadiazol-2-
yl}methyl]-2-(phenoxymethyl)-1H-benzimidazole (6h). Per-
centage yield 76%; m.p.204–210 C, IR (KBr) cm1: 738
(C-Br), 1083 (N–N), 1241 (C–O), 1604 (C‚N), 2917 (CH–Ar);
1H-NMR (DMSO-d6) d ppm: 5.57 (s, 2H, CH2), 5.85 (s, 2H,
OCH2), 6.99–7.82 (m, 13H, aromatic), EI-MS 461
(M+ + 1). Anal calcd for C23H17BrN4O2:C, 59.88; H, 3.71;
Br, 17.32; N, 12.15; O, 6.94 Found: C, 59.91; H, 3.69; Br,
17.28; N, 12.15; O, 6.87.
2.1.3.9. Synthesis of 1-[{5-(2-nitrophenyl)-1,3,4-oxadiazol-2-
yl}methyl]-2-(phenoxymethyl)-1H-benzimidazole (6i). Per-
centage yield 58%; m.p.226-230 C, IR (KBr) cm1: 1035
(N–N), 1239 (C–O), 1566 and 1350 (NO2), 1685 (C‚N),
3063 (CH–Ar); 1H-NMR (DMSO-d6) d ppm: 5.38 (s, 2H,
CH2), 5.61 (s, 2H, OCH2), 6.88–8.09 (m, 13H, aromatic), EI-
MS 428 (M+ + 1). Anal calcd for C23H17N5O4: C, 64.63; H,
4.01; N, 16.39; O, 14.97 Found: C, 64.60; H, 4.04; N, 16.42;
O, 14.95.
2.1.3.10. Synthesis of 1-[{5-(4-nitrophenyl)-1,3,4-oxadiazol-2-
yl}methyl]-2-(phenoxymethyl)-1H-benzimidazole (6j). Per-
centage yield 70%; m.p. 232–236 C, IR (KBr) cm1: 1036
(N–N) 1237 (C–O), 1287 and 1349 (NO2), 1598 (C‚C);
1H-
NMR (DMSO-d6) d ppm: 5.50 (s, 2H, CH2), 6.04 (s, 2H,
OCH2), 6.96–7.76 (m,13H, aromatic), EI-MS 428 (M
+ + 1).
Anal calcd for C23H17N5O4: C, 64.63; H, 4.01; N, 16.39; O,
14.97 Found: C, 64.65; H, 4.0; N, 16.36; O, 14.98.
2.1.3.11. Synthesis of 2-(phenoxymethyl)-1-[{5-(4-methoxy-
phenyl)-1,3,4-oxadiazol-2-yl}methyl]-1H-benzimidazole (6k).
Percentage yield 80%; m.p. 168–174 C, IR (KBr) cm1:
1028 (N–N), 1256 (C–O), 1610 (C‚N); 1H-NMR (DMSO-
d6) d ppm: 3.82 (s, 3H, OCH3), 5.51 (s, 2H, CH2), 6.01 (s,
2H, OCH2), 6.94–7.73 (m, 13H, aromatic), EI-MS 413(M+ + 1). Anal calcd for C24H20N4O3: C, 69.89; H, 4.89; N,
13.58; O, 11.64 Found: C, 69.92; H, 4.87; N, 13.54; O, 11.61.
2.1.3.12. Synthesis of 2-(phenoxymethyl)-1-[{5-(3,4-dime-
thoxyphenyl)-1,3,4-oxadiazol-2-yl}methyl]-1H-benzimidazole
(6l). Percentage yield 85%; m.p.182–186 C, IR (KBr) cm1:
1025 (N–N), 1240 (C–O), 1600 (C‚N), 3025 (CH–Ar); 1H-
NMR (DMSO-d6) d ppm: 3.83 (s, 6H, OCH3), 5.50 (s, 2H,
CH2), 6.00 (s, 2H, OCH2), 6.92–7.75 (m, 12H, aromatic), EI-
MS 443 (M+ + 1). Anal calcd for C25H22N4O4: C, 67.86; H,
5.01; N, 12.66; O, 14.46. Found: C, 67.83; H, 5.05; N, 12.67;
O, 14.48.
2.1.3.13. Synthesis of 1-[(5-benzyl-1,3,4-oxadiazol-2-
yl)methyl]-2-(phenoxy methyl)-1H-benzimidazole (6m). Per-
centage yield 75%; m.p.234-238 C, IR (KBr) cm1: 1034
(N–N), 1239 (C–O), 1610 (C‚N), 3178 (CH–Ar); 1H-NMR
(DMSO-d6) d ppm: 4.17 (s, 2H, CH2-benzilic), 4.96 (s, 2H,
CH2), 5.29 (s, 2H, OCH2), 6.96–7.66 (m, 14H, aromatic), EI-
MS 396 (M+); Anal calcd for C24H20N4O2: C, 72.71; H,
5.08; N, 14.13; O, 8.07 Found: C, 72.68; H, 5.11; N, 14.15;
O, 8.11.
2.1.3.14. Synthesis of 1-[{5-(phenoxymethyl-1,3,4-oxadiazol-2-
yl)methyl}]-2-(phenoxymethyl)-1H-benzimidazole (6n). Per-
centage yield 73%; m.p.224-230 C, IR (KBr) cm1: 1079
(N–N), 1220 (C–O), 1623 (C‚N), 3055 (CH–Ar); 1H-NMR
(DMSO-d6) d ppm: 4.61 (s, 2H, OCH2-phenoxy), 5.12 (s,
2H, CH2), 5.39 (s, 2H, OCH2), 6.97–7.67 (m, 14H, aromatic),
EI-MS 412 (M+). Anal calcd for C24H20N4O3: C, 69.89; H,
4.89; N, 13.58; O, 11.64 Found: C, 69.90; H, 4.85; N, 13.56;
O, 11.67.
2.1.3.15. Synthesis of 1-[{5-(naphthylmethyl-1,3,4-oxadiazol-2-
yl)methyl}]-2-(phenoxymethyl)-1H-benzimidazole (6o). Per-
centage yield 70%; m.p. 138–142 C, IR (KBr) cm1: 1036
(N–N), 1201 (C–O), 1711 (C‚N), 3158 (CH–Ar); 1H-NMR
(DMSO-d6) d ppm: 3.99 (s, 2H, CH2-naphthyl), 5.24 (s, 2H,
CH2), 5.51 (s, 2H, OCH2), 7.00–8.10 (m, 16H, aromatic), EI-
MS 446 (M+). Anal calcd for C28H22N4O2: C, 75.32; H,
4.97; N, 12.55; O, 7.17 Found: C, 75.29; H, 4.95; N, 12.59;
O, 7.20.
2.1.3.16. Synthesis of 1-[{5-(diphenylmethyl-1,3,4-oxadiazol-2-
yl)methyl}]-2-(phenoxymethyl)-1H-benzimidazole (6p). Per-
centage yield 79%; m.p. 152–158, IR (KBr) cm1: 1036 (N–
N), 1240 (C–O), 1613 (C‚N); 1H-NMR (DMSO-d6) d ppm:
5.16 (s, 2H, CH2-biphenyl), 5.42 (s, 2H, CH2), 5.96(s, 2H,
OCH2), 6.82–7.71 (m, 20H, aromatic), EI-MS 472 (M
+); Anal
calcd for C30H24N4O2: C, 76.25; H, 5.12; N, 11.86; O, 6.77
Found: C, 76.26; H, 5.15; N, 11.90; O, 6.80.3. Result and discussion
3.1. Chemistry
The reaction sequence for the titled compound is outlined in
Scheme 1. o-Phenylenediamine (1) and phenoxyacetic acid
(2) were used as starting material for the formation of 2-(phen-
oxymethyl)-1H-benzimidazole (3). The compound 3 on treat-
ment with ethylchloroacetate in the presence of anhydrous
NH2
NH2
+
O
CH2COOH
N
H
N O
ClCH2COOC2H5Dry acetone/K2CO3
N
N O
CH2COOC2H5
1 2 3
4
N
N O
O
N N
R
C2H5OHNHNH2.H2O
N
N O
CH2CONHNH2
5
RCOOH
POCl3
4NHCl
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6a-p
Scheme 1 R=C6H5, 2-CH3C6H4, 3-CH3C6H4, 4-CH3C6H4, 2-ClC6H4, 4-ClC6H4, 2-BrC6H4, 4-BrC6H4,, 2-NO2C6H4, 4-NO2C6H4,
4-OCH3C6H4, 3,4-diOCH3C6H3, C6H5CH2, C6H5OCH2, C10H7CH2, C12H9CH2.
Table 1 Antibacterial activity of compounds against Escherichia coli.
Compounds Concentrations
1 lg/ml 10 lg/ml 50 lg/ml 100 lg/ml 200 lg/ml 500 lg/ml App. MIC lg/ml
6a    + ++ ++ 200
6b   + + ++ ++ 200
6c-   + + ++ ++ 200
6d   + ++ +++ +++ 100
6e     + ++ 500
6f   + +++ +++ +++ 100
6g     + + 200
6h    +++ +++ +++ 100
6i      + 500
6j    + ++ ++ 200
6k     + + 200
6l    + + + 100
6m    + ++ ++ 200
6n     + + 200
6o    + ++ ++ 200
6p   + ++ ++ +++ 500
Oﬂoxacin  + + +++ +++ +++ 100
Symbols: (), no inhibition; (+), weakly active; (++), moderately active; (+++), highly active.
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methyl)-1H-benzimidazol-1-yl]acetate (4), which on treatment
with hydrazine hydrate resulted in the formation of 2-[2-
(phenoxymethyl)-1H-benzimidazol-1-yl]acetohydrazide (5),
ﬁnal intermediate 5 on condensation with various aromatic
acids in the presence of phosphorous oxychloride at a
temperature of 110–120 C resulted in the formation of2-(phenoxymethyl)-1-[(5-substituted-1,3,4-oxadiazol-2-yl)methyl]
-1H-benzimidazole (6a–p).
3.2. Antibacterial activity test
The synthesized compounds 6a–p were screened for antibacte-
rial activity against S. aureus and E. coli by agar diffusion
Table 2 Antibacterial activity of compounds against S. aureus.
Compounds Concentrations
1 lg/ml 10 lg/ml 50 lg/ml 100 lg/ml 200 lg/ml 500 lg/ml App. MIC lg/ml
6a    + + ++ 500
6b   + + ++ ++ 200
6c     + ++ 500
6d   + +++ +++ +++ 100
6e     ++ ++ 200
6f   + ++ ++ ++ 100
6g    + + ++ 500
6h   + +++ ++++ +++ 100
6i      + 500
6j    + ++ ++ 200
6k    + ++ ++ 200
6l   + +++ +++ +++ 100
6m    + ++ +++ 500
6n    ++ ++ ++ 100
6o     ++ ++ 200
6p   + ++ ++ +++ 500
Oﬂoxacin + + +++ +++ +++ 100
Symbols: (), no inhibition; (+), weakly active; (++), moderately active; (+++), highly active.
Table 3 Antifungal activity of compounds against Candida
albicans and Aspergillus ﬂavus.
Compounds Zone of inhibition (50 and 100 lg/ml)
Candida albicans Aspergillus ﬂavus
50 lg/ml 100 lg/ml 50 lg/ml 100 lg/ml
6a + ++  +
6b ++ ++ + ++
6c + +  +
6d ++ +++ ++ +++
6e  ++ + ++
6f + +++ +++ +++
6g ++ ++ + ++
6h ++ ++ ++ ++
6i ++ ++ ++ ++
6j + ++ ++ ++
6k  +  
6l ++ +++ ++ +++
6m + +  +
6n  + + ++
6o + ++ + ++
6p ++ ++ + ++
Ketoconazole ++ +++ ++ +++
Symbols: (), no inhibition (>10 mm); (+), weakly active (10–
14 mm); (++), moderately active (15–20 mm); (+++), highly
active (20–30 mm); (+++), ketoconazole.
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zone of inhibition exhibited by the compounds was measured.
It was found that compounds 6d, 6f and 6h were the most ac-
tive against E. coli at a concentration of 100 lg/ml. The com-
pounds screened against S. aureus, compounds 6d, 6h and 6l
were the most active against S. aureus at a concentration of
100 lg/ml.
3.3. Antifungal activity test
For the antifungal activity the synthesized compounds 6a–p
were tested for antifungal activity against Aspergillus ﬂavus
and Candida albicans by agar diffusion technique using keto-
conazole as reference. The diameter of the zone of inhibition
exhibited by the compounds was measured and it was found
that the compounds 6d, 6f and 6l were the most active.
4. Conclusion
The development of oxadiazole bearing benzimidazole system
has new potentially active antibacterial and antifungal agents.
The results of in vitro antimicrobial activities showed that the
compounds having deactivating group (electron withdrawing
group like NO2, Br and Cl) and weakly activating group i.e.,
CH3 group were the most active against E. coli and S. aureus.
The antifungal activity conﬁrmed that the compound having
Cl, NO2, Br and methyl group in the oxadiazole system
(Table 3) is the most potent against A. ﬂavus and C. albicans
respectively.
5. Biological activities
The synthesized compound (6a–p), were screened for antibac-
terial activity against S. aureus and E. coli by agar diffusion
technique using oﬂoxacin as the reference (50 lg/ml), anti-
fungal activity against A. ﬂavus and C. albicans by agar diffu-sion technique using ketoconazole as reference (50 lg/ml). Six
concentrations of test compounds i.e., 1, 10, 50, 100 200 and
500 lg/ml were chosen for evaluation. The diameter of the
zone of inhibition exhibited by the compounds was measured.
The observations are outlined in Tables 1–3.
The antifungal activity of compounds (6a–p) was evaluated
by using a cup plate agar diffusion method against Aspergillus
niger and A. ﬂavus fungal strains using ketoconazole as stan-
dard. The zone of inhibition exhibited standard with MIC
(oﬂoxacin) was considered as the highest growth inhibition
S508 Salahuddin et al.and indicated by +++ and all the test compounds were eval-
uated on the same scale.
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